-
CHS survey of people with hemophilia A and their caregivers
In June and July 2024, the Canadian Hemophilia Society conducted an online survey regarding the lived experience of people with hemophilia A and their caregivers....
-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Conflicting opinions on gene therapies from Canada’s two HTA agencies
Montreal, July 5, 2024 – Canada’s two health technology assessment (HTA) agencies have made conflicting recommendations on two gene therapies for hemophilia B. Earlier in...
-
The proven importance of data
In the context of the WFH 2024 World Congress, I was invited to present at the Data and Research Workshop on April 21 about how...